2022 World Conference on Lung Cancer (ePosters)-EP14.03-002. Low-Dose Radiotherapy Plus Sugemalimab in Second-Line Treatment for Advanced-Stage Small-Cell Lung Cancer: Initial Results of a Phase I Study

EP14.03-002. Low-Dose Radiotherapy Plus Sugemalimab in Second-Line Treatment for Advanced-Stage Small-Cell Lung Cancer: Initial Results of a Phase I Study

Back to course

Pdf Summary

A phase I study conducted by the Cancer Center at West China Hospital, Sichuan University, aimed to evaluate the safety and efficacy of combining low-dose radiotherapy with the immune-checkpoint inhibitor Sugemalimab in the second-line treatment of small-cell lung cancer (SCLC). The study enrolled 11 patients who had relapsed or progressed SCLC, and they were divided into three groups receiving different doses of radiation. Sugemalimab was administered alongside radiation and continued every three weeks for up to 12 months.<br /><br />The initial results showed that the combination therapy was well tolerated by the patients. Out of the 11 patients, five experienced treatment-related adverse events (TRAEs), and two had grade 3 or higher TRAEs. However, no cases of radiation-induced or ICI-induced pneumonitis were observed. Nine patients completed at least one tumor assessment, and two of them achieved confirmed partial responses. The overall response rate was 18.2%, and the disease control rate was 45.5%.<br /><br />The study concluded that the combination of low-dose radiotherapy and Sugemalimab demonstrated clinical tolerability and safety. The researchers are now considering conducting a prospective phase II study to further investigate the effectiveness of this combination therapy.<br /><br />Overall, this preliminary study suggests that combining low-dose radiotherapy with Sugemalimab may be a promising option for patients with relapsed or progressed SCLC. However, further research is needed to determine the long-term efficacy and safety of this treatment approach.

Asset Subtitle

Youling Gong

Meta Tag

Speaker Youling Gong

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - RT

Keywords

Sugemalimab

small-cell lung cancer

SCLC

low-dose radiotherapy

immune-checkpoint inhibitor

treatment-related adverse events

clinical tolerability

prospective phase II study

efficacy

safety